More suggested changes to osteopathic medical curriculum

To the Editor:

Dr Papa's article, "Part 2: Readdressing the function and structure of colleges of osteopathic medicine" (JAOA 1993;93:701-704, 707-708), presents some intriguing reform proposals. I agree with several, but not all, of his suggestions.

Although excellent, the suggestion of incorporating intensive clinical topics early in the curriculum has a flaw. The focus here is disease-oriented. This focus may serve as a practical expedient, but our founder, Andrew Taylor Still, admonished us, "Seek health. Anyone can find disease."

The article seems to emphasize the cognitive aspects of learning. Where are the behavioral and psychomotor skills in early osteopathic medical training? Obviously, osteopathic manipulation skills must be a part of any new curriculum as must diagnostic skills. I suggest that some observation of experienced clinicians be included as part of the early clinical incentives. In this way, students are given a "reality check" on the cognitive knowledge garnered in the classroom. Such observation would reinforce the students' learning.

Academic deans or medical school administrators should be trained and experienced medical educators, just as the medical faculty should be as suggested by Dr Papa in his article. The academic deans should be the educational leaders—and educators. In my days as an osteopathic medical educator and faculty member, I knew many researchers who never became educators and many educators who never became researchers. The widest reform capitalizes on the talents and diversity of unique individuals to achieve a common, esteemed goal.

Finally, on a philosophic note, research is good, but we DOs need to recover the belief in osteopathic medicine that our predecessors had. It was during that time when our fastest growth as a profession occurred. If we need more research to convince ourselves of the value of our profession, then we will have trouble convincing those persons outside of the profession of our value. During our first century, the osteopathic medical profession has done much research. We should never stop our research. However, we must ask ourselves, "How much proof is it going to take to convince those persons who have chosen not to believe in osteopathic medicine to believe?"

We need more stimulation for self-study such as that provided by Dr Papa's article. We must also remember that no one person has the complete answer.

Robert C. Clark, DO, MS (Higher Education)
Upland, Calif

Response

To the Editor:

Dr Clark is correct when he writes that I emphasize diseases and their treatments in my proposed problem-oriented, multidiscipline-developed learning segment (POMDLS) approach to medical instruction. However, I must remind him that the focus of all presentations lies on "problems" (chest pains and dyspnea, for example) and not "diseases." As I note in my article, this shift from focusing exclusive attention on diseases to addressing problems makes it possible to devote time within each POMDLS for disease prevention and health promotion concepts. Thus, this switch will provide a more appropriate and coherent (problem-oriented) context in which students can learn. It would also provide a more supportive environment for fostering the health promotion/disease prevention concepts to which the osteopathic medical profession aspires.

Furthermore, I do support the notion that students be given early and frequent exposure to patients, as suggested on page 703 in my article, "At appropriate times during these segments, the clinical faculty would provide real or simulated patient presentations for problem-solving sessions." This statement is not meant to exclude time spent in the actual clinical environment.

In fact, a POMDLS curriculum approach would enhance the institution's ability to allow first- and second-year students to have blocks of time devoted to clinical situations. For example, first-year students could, in their first 2 months, experience POMDLS dealing with hypertension, diarrhea, pediatric fever, and the like, and then spend
SUMMARY OF PRESCRIBING INFORMATION
(See package insert for full prescribing information)

CLINICAL PHARMACOLOGY
Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the amphetamines. Actions include CNS stimulation, blood pressure elevation, tachycardia and hyperglycemia. However, the amphetamines have not been proved to act primarily by appetite suppression; other actions—CNS or metabolic—may be involved.

Obese adults treated with drug and diet lose more weight than those treated with placebo and diet, in short-term studies. The difference in weight loss averages a fraction of a pound a week. The amount of weight loss varies from trial to trial, and is influenced by the physician, the population treated, and the diet as well as the drug. The studies cited are of a few weeks' duration, while obesity goes on for years, thus the total impact of the drug must be considered clinically limited.

INDICATIONS AND USAGE
In the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors (see below).

CONTRAINDICATIONS
Advanced atherosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, hypertension or idiopathic or glaucoma, agitation states, drug abuse. During or within 14 days after administration of monoamine oxidase inhibitors.

WARNINGS
Tolerance to the anorectic effect develops within a few weeks: discontinue drug rather than exceeding recommended dose. The patient should be cautioned about operating machinery or driving.

Since phentermine is related to the amphetamines, the possibility of abuse must be considered. Patients may increase the dosage to many times that recommended. Abrupt cessation of prolonged high dosage results in severe CNS adverse effects. Chronic intoxication with anorectics may produce dermatoses, insomnia, irritability, hyperactivity, personality changes. The most severe effect is a psychosis resembling schizophrenia.

Usage in Pregnancy: No reproduction studies or teratology studies of phentermine hydrochloride in animals or humans, have been published. Therefore, use of phentermine hydrochloride by women who are or may become pregnant requires that the potential benefit be weighed against the possible hazard to mother and infant.

Usage in Children: Not recommended for use in children under 12 years.

Usage with Alcohol: Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.

PRECAUTIONS
Caution should be exercised in prescribing phentermine for patients with mild hypertension or diabetes mellitus. Phentermine may reduce the hypotensive effect of guanethidine. The least amount feasible should be prescribed or dispensed at one time.

ADVERSE REACTIONS
Cardiovascular (palpitation, tachycardia, B.P. elevation); CNS (overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, psychic episodes); GI (mouth dryness, unpleasant taste, diarrhea, constipation, other); Allergic (urticaria); Endocrine (impotence, altered libido).

DOSEAGE AND ADMINISTRATION
One capsule or tablet daily, before breakfast or 1-2 hours after breakfast. Dosage may be adjusted to the patient's need.

OVERDOSAGE
Acute overdose produces restlessness, tremor, hyperreflexia, rapid respiration, confusion, associative behavior, hallucinations, pain states. Fatigue and depression usually follow CNS stimulation. CV effects: arrhythmias, hyper- or hypotension, circulatory collapse. GI symptoms: nausea, vomiting, diarrhea, cramps. Convulsions and coma usually precede death.

Management of acute poisoning is symptomatic, e.g., lavage and sedation. Experience with dialysis is inadequate. Ruthenium red promotes drug excretion. IV phentolamine has been suggested for acute severe hypertension.

HOW SUPPLIED
List No. 9, bottles of 100, 400 and 1000 tablets. List No. 19, bottles of 100 capsules.

ADIPEX-P® (phentermine HCI 37.5 mg)